Quick Answer
Protagenic Therapeutics, Inc.new reported Diluted EPS of $1.13 per share (loss) for fiscal year 2024.
Protagenic Therapeutics, Inc.new Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.13 | +1.7% |
| 2023 | -$1.15 | -40.2% |
| 2022 | -$0.82 | — |
| 2014 | $0.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.14 | +812.5% | +342.6% |
| September 30, 2025 | -$0.47 | -327.3% | +82.9% |
| March 31, 2025 | -$2.75 | +49.4% | -1618.8% |
| December 31, 2024 | -$0.16 | — | -45.5% |
| September 30, 2024 | -$0.11 | +65.6% | +69.4% |
| June 30, 2024 | -$0.36 | -28.6% | +93.4% |
| March 31, 2024 | -$5.44 | -3100.0% | -1600.0% |
| September 30, 2023 | -$0.32 | -52.4% | -14.3% |
- Protagenic Therapeutics, Inc.new showed an increase of +1.7% in Diluted EPS compared to the prior fiscal year.
- The most recent figure is from Protagenic Therapeutics, Inc.new’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: